# Yasuo Miyoshi

## List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| 140 papers | 5,192 citations | 94433 <br> 37 h-index | 98798 <br> 67 g-index |
| 143 all docs | 143 docs citations | 143 times ranked | 7508 citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Abstract P4-07-26: Clinical impact of tumor infiltrating lymphocytes and neutrophil-lymphocyte ratio in estrogen receptor-positive/HER2-negative breast cancer patients with high 21-gene signature recurrence scores. Cancer Research, 2022, 82, P4-07-26-P4-07-26. | 0.9 | 0 |
| 2 | Harmonized pretreatment quantitative volume-based FDG-PET/CT parameters for prognosis of stage I-III breast cancer: Multicenter study. Oncotarget, 2021, 12, 95-105. | 1.8 | 14 |
| 3 | HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN. Scientific Reports, 2021, 11, 360. | 3.3 | 8 |
| 4 | Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer. EJNMMI Research, 2021, 11, 10. | 2.5 | 20 |
| 5 | Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan. Breast Cancer, 2021, 28, 945-955. | 2.9 | 6 |
| 6 | Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer, 2021, 28, 1038-1050. | 2.9 | 10 |
| 7 | Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13). Anticancer Research, 2021, 41, 3121-3126. | 1.1 | 0 |
| 8 | Breast cancer diffuse liver metastasis with high liver stiffness using ultrasound elastography. Acta Hepatologica Japonica, 2021, 62, 647-655. | 0.1 | 0 |
| 9 | Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC). American Journal of Cancer Research, 2021, 11, 5743-5755. | 1.4 | 1 |
| 10 | Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes. Anticancer Research, 2020, 40, 2871-2880. | 1.1 | 16 |
| 11 | High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician's choice—in the EMBRACE study. Breast Cancer, 2020, 27, 706-715. | 2.9 | 41 |
| 12 | C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin. Anticancer Research, 2020, 40, 4147-4156. | 1.1 | 10 |
| 13 | Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes. Anticancer Research, 2020, 40, 2141-2150. | 1.1 | 11 |
| 14 | Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Science, 2020, 111, 209-218. | 3.9 | 23 |
| 15 | Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget, 2020, 11, 86-98. | 1.8 | 15 |
| 16 | The GALNT6–LGALS3BP axis promotes breast cancer cell growth. International Journal of Oncology, 2020, 56, 581-595. | 3.3 | 9 |
| 17 | A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site. Anticancer Research, 2019, 39, 5653-5662. | 1.1 | 8 |
| 18 | High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. Anticancer Research, 2019, 39, 5009-5018. | 1.1 | 17 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 19 | Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Research and Treatment, 2019, 176, 631-635. | 2.5 | 4 |
| 20 | Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negativeÂoperated breast cancers. Breast Cancer, 2019, 26, 738-747. | 2.9 | 21 |
| 21 | Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy. Annals of Surgical Oncology, 2019, 26, 2175-2183. | 1.5 | 16 |
| 22 | Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. Scientific Reports, 2019, 9, 1811. | 3.3 | 22 |
| 23 | Abstract 5313: Frequent downregulation ofSALL3by genetic and epigenetic alterations is involved in progression and chemoresistance of triple negative breast cancers. , 2019, , . | | 0 |
| 24 | Abstract 3813: PHB2 inactivation by AKAP-BIG3 is required for progression of HER2-overexpressing breast cancer. , 2019, , . | | 0 |
| 25 | Prognostic value of F-FDG PET/CT prior to breast cancer treatment. Comparison with magnetic resonance spectroscopy and diffusion weighted imaging. Hellenic Journal of Nuclear Medicine, 2019, 22, 25-35. | 0.3 | 3 |
| 26 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). Cancer Chemotherapy and Pharmacology, 2018, 81, 755-762. | 2.3 | 8 |
| 27 | Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel. Clinical Breast Cancer, 2018, 18, 400-409. | 2.4 | 44 |
| 28 | Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Breast Cancer Research and Treatment, 2018, 168, 135-145. | 2.5 | 27 |
| 29 | Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer, 2018, 25, 392-401. | 2.9 | 134 |
| 30 | Prognostic value of FDG-PET and DWI in breast cancer. Annals of Nuclear Medicine, 2018, 32, 44-53. | 2.2 | 34 |
| 31 | Improved prognosis of low baseline neutrophilâ€'toâ€'lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Molecular and Clinical Oncology, 2018, 10, 275-284. | 1.0 | 12 |
| 32 | Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. JCO Precision Oncology, 2018, 2, 1-13. | 3.0 | 3 |
| 33 | Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer. International Journal of Oncology, 2018, 52, 1539-1558. | 3.3 | 8 |
| 34 | HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA. Cancer Research, 2018, 78, 6371-6385. | 0.9 | 41 |
| 35 | Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer, 2018, 18, 982. | 2.6 | 33 |
| 36 | Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST â€" multicenter study in Japan. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1661-1671. | 6.4 | 23 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | High levels of serum CA15â€3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with nonâ€pathological complete response after neoadjuvant chemotherapy. Journal of Surgical Oncology, 2018, 118, 228-237. | 1.7 | 4 |
| 38 | Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World Journal of Surgical Oncology, 2018, 16, 26. | 1.9 | 17 |
| 39 | Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. Journal of Clinical Investigation, 2018, 128, 5603-5619. | 8.2 | 39 |
| 40 | Tumor mutation burden in triple negative breast cancer patients in Japan.. Journal of Clinical Oncology, 2018, 36, e13111-e13111. | 1.6 | 12 |
| 41 | Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0. Nagoya Journal of Medical Science, 2018, 80, 183-197. | 0.3 | 15 |
| 42 | C-reactive Protein Level on Postoperative Day One is Associated with Chronic Postsurgical Pain After Mastectomy. Anesthesiology and Pain Medicine, 2018, 8, e79331. | 1.3 | 8 |
| 43 | Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer. Translational Cancer Research, 2018, 7, S514-S518. | 1.0 | 0 |
| 44 | A claims data analysis of single institution for comorbidity among various types of cancer.. Journal of Clinical Oncology, 2018, 36, e18843-e18843. | 1.6 | 0 |
| 45 | Abstract 1837: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer by utilizing PHB2, a tumor suppressor of multiple resistance pathways. , 2018, , . | | 0 |
| 46 | Abstract 5315: Frequent downregulation of SALL3 by recurrent genetic and epigenetic alterations is involved in triple-negative breast cancers. Cancer Research, 2018, 78, 5315-5315. | 0.9 | 1 |
| 47 | Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. Breast Cancer, 2017, 24, 245-253. | 2.9 | 8 |
| 48 | A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells. Nature Communications, 2017, 8, 15427. | 12.8 | 14 |
| 49 | Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics. Scientific Reports, 2017, 7, 1821. | 3.3 | 11 |
| 50 | Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. Breast Cancer, 2017, 24, 528-534. | 2.9 | 3 |
| 51 | Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. PLoS ONE, 2017, 12, e0184508. | 2.5 | 6 |
| 52 | Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget, 2017, 8, 62029-62038. | 1.8 | 28 |
| 53 | Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes. Breast, 2016, 30, 5-12. | 2.2 | 31 |
| 54 | HP1 regulates the localization of FANCJ at sites of DNA doubleâ€strand breaks. Cancer Science, 2016, 107, 1406-1415. | 3.9 | 14 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 55 | Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. International Journal of Clinical Oncology, 2016, 21, 254-261. | 2.2 | 19 |
| 56 | Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. International Journal of Oncology, 2016, 49, 471-478. | 3.3 | 32 |
| 57 | Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer, 2016, 23, 224-230. | 2.9 | 9 |
| 58 | Present and future role of FDG-PET/CT imaging in the management of breast cancer. Japanese Journal of Radiology, 2016, 34, 167-180. | 2.4 | 25 |
| 59 | Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma. European Journal of Radiology, 2016, 85, 943-949. | 2.6 | 61 |
| 60 | Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. Japanese Journal of Radiology, 2016, 34, 220-228. | 2.4 | 14 |
| 61 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. International Journal of Clinical Oncology, 2016, 21, 262-269. | 2.2 | 19 |
| 62 | Overall survival of participants compared to non-participants in a randomized-controlled trial (SELECT BC): A prospective cohort study.. Journal of Clinical Oncology, 2016, 34, 2527-2527. | 1.6 | 0 |
| 63 | High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. Breast Cancer Research and Treatment, 2015, 154, 521-531. | 2.5 | 6 |
| 64 | Therapeutic advances in <scp>BIG</scp>3â€<scp>PHB</scp>2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. Cancer Science, 2015, 106, 550-558. | 3.9 | 11 |
| 65 | BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells. PLoS ONE, 2015, 10, e0127707. | 2.5 | 19 |
| 66 | Class I histone deacetylase inhibitors inhibit the retention of <scp>BRCA</scp>1 and 53<scp>BP</scp>1 at the site of <scp>DNA</scp> damage. Cancer Science, 2015, 106, 1050-1056. | 3.9 | 28 |
| 67 | Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2â^' Breast Cancer. Clinical Breast Cancer, 2015, 15, 197-203. | 2.4 | 14 |
| 68 | Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. Cancer Research, 2015, 75, 1311-1321. | 0.9 | 83 |
| 69 | Association between 18F-FDG uptake and molecular subtype of breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1371-1377. | 6.4 | 62 |
| 70 | Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer, 2015, 22, 235-244. | 2.9 | 58 |
| 71 | High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead toÂa Worse Prognosis for Postmenopausal PatientsÂWith Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 204-211. | 2.4 | 33 |
| 72 | C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis. Breast Cancer, 2015, 22, 366-373. | 2.9 | 7 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 73 | Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. Breast Cancer, 2015, 22, 399-405. | 2.9 | 10 |
| 74 | Abstract P5-09-05: Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation. , 2015, , . | | 0 |
| 75 | Abstract P1-12-04: Factors influencing on discontinuation of adjuvant anastrozole in postmenopausal Japanese breast cancer patients: Results from a prospective multicenter cohort study of patient-reported outcomes. , 2015, , . | | 0 |
| 76 | Class I HDAC inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.. Journal of Clinical Oncology, 2015, 33, e13552-e13552. | 1.6 | 1 |
| 77 | Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer, 2014, 21, 52-57. | 2.9 | 9 |
| 78 | Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. International Journal of Clinical Oncology, 2014, 19, 467-472. | 2.2 | 14 |
| 79 | Strategy for treatment of isolated contralateral supraclavicular recurrence in patient with breast cancer after sentinel lymph node biopsy without axillary lymph node dissection. International Cancer Conference Journal, 2014, 3, 133-139. | 0.5 | 0 |
| 80 | Involvement of B3GALNT2 overexpression in the cell growth of breast cancer. International Journal of Oncology, 2014, 44, 427-434. | 3.3 | 11 |
| 81 | Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. Scientific Reports, 2014, 4, 7355. | 3.3 | 68 |
| 82 | Effect of body mass index and menopausal disorders during menopause on vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes.. Journal of Clinical Oncology, 2014, 32, 9619-9619. | 1.6 | 0 |
| 83 | Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Research, 2014, 34, 3583-8. | 1.1 | 2 |
| 84 | Targeting BIG3â€"PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nature Communications, 2013, 4, 2443. | 12.8 | 63 |
| 85 | Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. International Journal of Oncology, 2013, 42, 478-506. | 3.3 | 104 |
| 86 | Phase I clinical trial of multi-antigen peptide vaccines therapy using cancer-testis antigens for patients with advanced or recurrent breast cancer.. Journal of Clinical Oncology, 2012, 30, e13037-e13037. | 1.6 | 3 |
| 87 | Mechanisms of estrogen receptor-Î± upregulation in breast cancers. Medical Molecular Morphology, 2010, 43, 193-196. | 1.0 | 36 |
| 88 | Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer, 2010, 17, 103-109. | 2.9 | 15 |
| 89 | Prediction of hormone sensitivity for breast cancers. Breast Cancer, 2010, 17, 86-91. | 2.9 | 13 |
| 90 | Association of loss of BRCA1 expression with centrosome aberration in human breast cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 421-430. | 2.5 | 23 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 91 | Breast cancer risk assessment for possible tailored screening for Japanese women. Breast Cancer, 2009, 16, 243-247. | 2.9 | 5 |
| 92 | Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Research and Treatment, 2008, 112, 405-410. | 2.5 | 84 |
| 93 | Basal-like subtype and BRCA1 dysfunction in breast cancers. International Journal of Clinical Oncology, 2008, 13, 395-400. | 2.2 | 32 |
| 94 | Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers. Journal of Cancer Research and Clinical Oncology, 2008, 134, 561-567. | 2.5 | 11 |
| 95 | Potential of Reduction in Total Tumor Volume Measured with 3D-MRI as a Prognostic Factor for Locally-Advanced Breast Cancer Patients Treated with Primary Chemotherapy. Breast Journal, 2008, 14, 523-531. | 1.0 | 17 |
| 96 | Quantitative assessment of mammographic density and breast cancer risk for Japanese women. Breast, 2008, 17, 27-35. | 2.2 | 33 |
| 97 | Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast. Surgery, 2008, 143, 414-425. | 1.9 | 96 |
| 98 | Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Letters, 2008, 262, 248-256. | 7.2 | 29 |
| 99 | Topoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers. Cancer Letters, 2008, 264, 44-53. | 7.2 | 12 |
| 100 | Prognostic Significance of CD55 Expression in Breast Cancer. Clinical Cancer Research, 2008, 14, 4780-4786. | 7.0 | 55 |
| 101 | Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women. Clinical Cancer Research, 2007, 13, 408-414. | 7.0 | 138 |
| 102 | Demonstration of Adiponectin Receptors 1 and 2 mRNA expression in human breast cancer cells. Cancer Letters, 2007, 250, 229-236. | 7.2 | 77 |
| 103 | Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. Breast Cancer Research and Treatment, 2007, 106, 11-17. | 2.5 | 72 |
| 104 | Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. Journal of Cancer Research and Clinical Oncology, 2007, 133, 501-509. | 2.5 | 18 |
| 105 | Quantitative analysis of aromatase, sulfatase and 17β-HSD1 mRNA expression in soft tissue metastases of breast cancer. Cancer Letters, 2006, 243, 23-31. | 7.2 | 19 |
| 106 | Preoperative Evaluation of Residual Tumor Extent by Three-Dimensional Magnetic Resonance Imaging in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Journal, 2006, 12, 130-137. | 1.0 | 77 |
| 107 | High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Science, 2006, 97, 523-529. | 3.9 | 85 |
| 108 | Association of GSTP1 CpG Islands Hypermethylation with Poor Prognosis in Human Breast Cancers. Breast Cancer Research and Treatment, 2006, 100, 169-176. | 2.5 | 57 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 109 | High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. International Journal of Cancer, 2006, 118, 1414-1419. | 5.1 | 157 |
| 110 | Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer, 2005, 12, 11-15. | 2.9 | 48 |
| 111 | Differentiation of Follicular Thyroid Adenoma from Carcinoma by Means of Gene Expression Profiling with Adapter-Tagged Competitive Polymerase Chain Reaction. Oncology, 2005, 69, 428-435. | 1.9 | 21 |
| 112 | Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling. Journal of Clinical Oncology, 2005, 23, 422-431. | 1.6 | 263 |
| 113 | Down-Regulation of *LATS1* and *LATS2* mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers. Clinical Cancer Research, 2005, 11, 1380-1385. | 7.0 | 278 |
| 114 | High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer. Clinical Cancer Research, 2005, 11, 8425-8430. | 7.0 | 162 |
| 115 | Down-Regulation of Intratumoral Aromatase Messenger RNA Levels by Docetaxel in Human Breast Cancers. Clinical Cancer Research, 2004, 10, 8163-8169. | 7.0 | 14 |
| 116 | Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Letters, 2004, 210, 197-203. | 7.2 | 55 |
| 117 | Prognostic significance of intra-tumoral estradiol level in breast cancer patients. Cancer Letters, 2004, 216, 115-121. | 7.2 | 11 |
| 118 | Increased Expression of BRCA1 mRNA Predicts Favorable Response to Anthracycline-Containing Chemotherapy in Breast Cancers. Breast Cancer Research and Treatment, 2003, 78, 45-50. | 2.5 | 35 |
| 119 | Current status of endocrine therapy for breast cancer. Breast Cancer, 2003, 10, 105-111. | 2.9 | 5 |
| 120 | Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomedicine and Pharmacotherapy, 2003, 57, 471-481. | 5.6 | 58 |
| 121 | Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. Cancer Letters, 2003, 195, 81-86. | 7.2 | 14 |
| 122 | Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clinical Cancer Research, 2003, 9, 1376-80. | 7.0 | 26 |
| 123 | Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clinical Cancer Research, 2003, 9, 2229-33. | 7.0 | 26 |
| 124 | Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clinical Cancer Research, 2003, 9, 2992-7. | 7.0 | 86 |
| 125 | Association of serum adiponectin levels with breast cancer risk. Clinical Cancer Research, 2003, 9, 5699-704. | 7.0 | 317 |
| 126 | Molecular classification of primary breast tumors possessing distinct prognostic properties. Human Molecular Genetics, 2002, 11, 199-206. | 2.9 | 54 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 127 | HighBRCA2 mRNA expression predicts poor prognosis in breast cancer patients. International Journal of Cancer, 2002, 98, 879-882. | 5.1 | 23 |
| 128 | Mutational analysis of the class I β-tubulingene in human breast cancer. International Journal of Cancer, 2002, 101, 46-51. | 5.1 | 49 |
| 129 | Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. International Journal of Cancer, 2002, 97, 129-132. | 5.1 | 93 |
| 130 | Quantitative analysis of estrogen receptor-α and -β messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Letters, 2001, 170, 91-97. | 7.2 | 26 |
| 131 | Decreased expression ofBRCA2 mRNA predicts favorable response to docetaxel in breast cancer. International Journal of Cancer, 2001, 95, 255-259. | 5.1 | 57 |
| 132 | Association of centrosomal kinaseSTK15/BTAK mRNA expression with chromosomal instability in human breast cancers. International Journal of Cancer, 2001, 92, 370-373. | 5.1 | 214 |
| 133 | Involvement of up-regulation of 17?-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. International Journal of Cancer, 2001, 94, 685-689. | 5.1 | 132 |
| 134 | Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast Cancer Research and Treatment, 2001, 67, 169-175. | 2.5 | 27 |
| 135 | | | |